A
BMRN icon

Astrantus’s BioMarin Pharmaceuticals BMRN Stock Holding History

Astrantus’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$347K Sell
4,500
-318
-7% -$26.6K 0.58% 87
2021
Q4 		$426K Buy
+4,818
New +$398K 0.32% 128

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Astrantus's BMRN Position: Q1 2022 in Review

Astrantus reduced its BioMarin Pharmaceuticals (BMRN) stake by 6.6% in Q1 2022, selling an estimated $26.6K and leaving 4,500 shares worth $347K. The position accounts for 0.58% of the portfolio, ranked #87.

Astrantus first reported a position in BMRN in Q4 2021 and has held it in 2 quarters since. The position peaked at $426K in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • Astrantus held 4,500 shares of BioMarin Pharmaceuticals worth $347K as of Q1 2022.
  • Astrantus sold 318 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $26.6K.
  • BioMarin Pharmaceuticals made up 0.58% of Astrantus's portfolio in Q1 2022, its #87 holding.
  • Astrantus first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Astrantus's BioMarin Pharmaceuticals position peaked at $426K in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.